Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Induction Therapy - Oxaliplatin Clear all
Active, not recruiting Phase 3 Interventional Results available

Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial

NCT01558921
View directory record Official record
Conditions
Rectal Cancer
Interventions
M1 scheme, standard long course chemoradiotherapy
Other
Lead sponsor
University Medical Center Groningen
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 4, 2026, 6:32 PM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

NCT05132504
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Pembrolizumab, Folfirinox
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 4, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

NCT02405585
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Interventions
mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)

NCT00525785
View directory record Official record
Conditions
Stomach Cancer, Gastric Cancer
Interventions
5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

NCT02270606
View directory record Official record
Conditions
Mucinous Adenocarcinoma of the Rectum, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Rectum, Rectal Adenocarcinoma, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer
Interventions
intensity-modulated radiation therapy, fluorouracil, oxaliplatin, leucovorin calcium, therapeutic conventional surgery
Radiation · Drug · Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 4, 2026, 6:32 PM EDT
Withdrawn Phase 2 Interventional

S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer

NCT00118105
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
bevacizumab, capecitabine, oxaliplatin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
46
States / cities
Los Angeles, California • Aurora, Illinois • Joliet, Illinois + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach

NCT00601705
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, epirubicin hydrochloride, fluorouracil, oxaliplatin, adjuvant therapy, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

NCT00081289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Radiation Therapy, Capecitabine 1650 mg/m^2/day, Capecitabine 1200 mg/m^2/day, Irinotecan, Oxaliplatin, Surgery, Folinic Acid, Fluorouracil
Radiation · Drug · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
5
States / cities
Sacramento, California • Miami, Florida • Harvey, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 4, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma

NCT03483038
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Liposomal Irinotecan, FOLFOX regimen
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Orlando, Florida • Tallahassee, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 4, 2026, 6:32 PM EDT
Active, not recruiting Phase 2 Interventional

Induction Chemotherapy for Locally Advanced Esophageal Cancer

NCT03110926
View directory record Official record
Conditions
Esophageal Carcinoma
Interventions
mFOLFOX6, Chemoradiation
Drug · Combination Product
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

NCT04456699
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Olaparib, 5-FU, Bevacizumab, Capecitabine, Leucovorin/ levoleucovorin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 4, 2026, 6:32 PM EDT
Terminated Phase 2 Interventional

Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

NCT00070265
View directory record Official record
Conditions
Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
oxaliplatin, capecitabine, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

NCT01488552
View directory record Official record
Conditions
Stage IV Pancreatic Cancer
Interventions
Gemcitabine, nab-paclitaxel, FOLFIRINOX, Immunohistochemistry (IHC) Analysis, Metformin, mFOLFIRI
Drug · Genetic
Lead sponsor
Pancreatic Cancer Research Team
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
5
States / cities
Scottsdale, Arizona • Burbank, California • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724
View directory record Official record
Conditions
CNS Germ Cell Tumor
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

NCT01580410
View directory record Official record
Conditions
Carcinoma of the Appendix, Primary Peritoneal Cavity Cancer
Interventions
mitomycin C, oxaliplatin, therapeutic conventional surgery, quality-of-life assessment, hyperthermic intraperitoneal chemotherapy
Drug · Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
3
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 4, 2026, 6:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

NCT05141721
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Fluoropyrimidine plus leucovorin, Bevacizumab
Drug
Lead sponsor
Seattle Project Corporation
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
43
States / cities
Gilbert, Arizona • Springdale, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 4, 2026, 6:32 PM EDT
Recruiting Phase 2 Interventional

Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma

NCT07222657
View directory record Official record
Conditions
Esophageal Adenocarcinoma, Esophageal Cancer
Interventions
Standard of care chemotherapy, LNSC
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer

NCT00193128
View directory record Official record
Conditions
Esophagus Cancer
Interventions
Oxaliplatin, Docetaxel, Capecitabine, Radiation therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Beverly Hills, California • Jacksonville, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Neoadjuvant FOLFIRINOX

NCT02178709
View directory record Official record
Conditions
Resectable Pancreatic Ductal Adenocarcinoma
Interventions
FOLFIRINOX
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 1 Interventional

Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer

NCT01446458
View directory record Official record
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
Interventions
Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery

NCT00408564
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, oxaliplatin, conventional surgery, radiation therapy, Gemcitabine
Biological · Drug · Procedure + 1 more
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2018 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04097028
View directory record Official record
Conditions
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Trifluridine and Tipiracil Hydrochloride, Oxaliplatin
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Buffalo, New York • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 4, 2026, 6:32 PM EDT
Completed Phase 2 Interventional Results available

Five Fractions of Radiotherapy Followed by Full Dose FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer

NCT01060007
View directory record Official record
Conditions
Rectal Neoplasms
Interventions
External beam radiation, Oxaliplatin, Leucovorin, 5-FU, Capecitabine
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 4, 2026, 6:32 PM EDT
Recruiting Not applicable Interventional

Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma

NCT07340151
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Surgical resection
Procedure
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 4, 2026, 6:32 PM EDT